Table 2.
Baseline characteristics of the per protocol population (site implanted)
| RVA (92) | RVS (90) | P-value | Total (182) | |
|---|---|---|---|---|
| Men (%) | 73.9 | 71.1 | 0.741 | 72.5 |
| Age (years) | 64.1 ± 9.7 | 62.5 ± 9.8 | 0.300 | 63.3 ± 9.8 |
| NYHA class II (%) | 5.4 | 10.1 | 0.376 | 7.7 |
| NYHA class III (%) | 90.2 | 85.4 | 87.8 | |
| NYHA class IV ambulatory (%) | 4.3 | 4.5 | 4.4 | |
| Ischaemic cardiomyopathy (%) | 27.2 | 25.6 | 0.867 | 26.4 |
| LVEF (%) | 29.9 ± 7.7 | 29.7 ± 8.2 | 0.940 | 30 ± 8 |
| LVESV (mL) | 154 ± 72 | 158 ± 83 | 0.734 | 156 ± 77 |
| Baseline medication | ||||
| Diuretics (%) | 83.7 | 86.7 | 0.678 | 85.2 |
| ACE inhibitor or ARB (%) | 93.7 | 95.7 | 0.747 | 94.7 |
| Aldosterone antagonist (%) | 38.0 | 40.0 | 0.879 | 39.0 |
| Beta-blocker (%) | 90.2 | 91.1 | 1.000 | 90.7 |
| ICD indication for primary prevention (%) | 98.9 | 97.8 | 0.619 | 98.4 |
| QRS duration (ms) | 160.1 ± 21.4 | 159.2 ± 23.0 | 0.730 | 159.6 ± 22.1 |
| >150 ms (%) | 70.8 | 62.5 | 0.267 | 66.7 |
| LBBB (%) | 85.7 | 81.8 | 0.643 | 83.8 |
| Intrinsic QRS axis (°) | −12 ± 53 | −12 ± 46 | 0.8 | −12 ± 49 |
| RV lead procedural data | ||||
| R wave (mV) | 14.1 ± 6.9 | 12.9 ± 6.5 | 0.256 | 13.5 ± 6.7 |
| RV pacing threshold (V/0.5 ms) | 0.8 ± 0.3 | 0.7 ± 0.3 | 0.035 | 0.8 ± 0.3 |
| RV lead impedance (Ω) | 761 ± 175 | 682.4 ± 165 | <0.001 | 721.7 ± 174 |
| Paced QRS duration (ms) | 140.0 ± 26.0 | 136.6 ± 25.7 | 0.201 | 138.3 ± 25.9 |
| Paced QRS axis (°) | 31 ± 136 | 56 ± 108 | 0.16 | 44 ± 123 |
Values are means ± SD, or % unless otherwise indicated. All between-groups differences are statistically non-significant except for RV lead impedance.
NYHA, New York Heart Association; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; LBBB, left bundle block branch.